Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 47, Issue 11

Issues

Molecular diagnostics in acute leukemias

Ulrike Bacher
  • Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Susanne Schnittger / Claudia Haferlach / Torsten Haferlach
Published Online: 2009-10-12 | DOI: https://doi.org/10.1515/CCLM.2009.324

Abstract

Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) both represent highly heterogeneous entities on the basis of diverse cyto- and molecular genetic alterations with considerable influence on prognosis and therapeutic decisions. In recent years, insights into the complex network of molecular markers underlying this diversity have shown marked progress due to the detection of novel mutations, such as nucleophosmin gene (NPM1) in AML, and due to the description of cooperation pathways in leukemogenesis. Also, targeted therapeutic strategies are continuously expanding as illustrated by the tyrosine kinase inhibitor (TKI) imatinib for BCR-ABL positive ALL. Thus, molecular analysis based on various techniques, such as polymerase chain reaction (PCR) has become an essential part of the diagnostic panel for acute leukemia. In addition, cytomorphology, cytogenetics, fluorescence in situ hybridization (FISH), and immunophenotyping with multiparameter flow cytometry (MFC) need to be applied for diagnosis. During the course of disease, the residual leukemic cell load can be monitored by highly sensitive quantitative PCR techniques (“real-time PCR”). At present, new techniques, such as high throughput sequencing (next generation sequencing, NGS) or gene expression profiling with microarrays are being explored for use in hematological malignancies, and are being evaluated in preclinical studies. This demonstrates that molecular diagnostics for acute leukemias are in continuous development. This review summarizes the most important recurrent molecular markers seen in acute leukemias, their role in prognosis and therapy and provides an overview on the relevant PCR techniques.

Clin Chem Lab Med 2009;47:1333–41.

Keywords: acute lymphoblastic leukemia; acute myeloid leukemia; molecular diagnostics; polymerase chain reaction; risk categorization

About the article

Corresponding author: Prof. Dr. med. Dr. phil. Torsten Haferlach, MD, MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377 Munich, Germany Phone: +49 89 99017-100, Fax: +49 89 99017-109,


Received: 2009-07-20

Accepted: 2009-08-17

Published Online: 2009-10-12

Published in Print: 2009-11-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 47, Issue 11, Pages 1333–1341, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2009.324.

Export Citation

©2009 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Zhiyong Wang, Erdjan Salih, Chinaemere Igwebuike, Ryan Mulhern, Ramon G. Bonegio, Andrea Havasi, and Steven C. Borkan
Journal of the American Society of Nephrology, 2019, Volume 30, Number 1, Page 50
[2]
Jorge Andrade, Suzanne M. Cox, and Samuel L. Volchenboum
Advances in Molecular Pathology, 2018, Volume 1, Number 1, Page 135
[3]
James M. Ziai and Alexa J. Siddon
American Journal of Clinical Pathology, 2015, Volume 144, Number 4, Page 539
[4]
Francis Lacombe, Lydia Campos, Kaoutar Allou, Christine Arnoulet, Adrienne Delabarthe, Florent Dumezy, Jean Feuillard, Franck Geneviève, Estelle Guérin, Julien Guy, Hélène Jouault, Pascale Lepelley, Marc Maynadié, Françoise Solly, Orianne Wagner Ballon, Claude Preudhomme, André Baruchel, Hervé Dombret, Norbert Ifrah, and Marie C. Béné
Hematological Oncology, 2017
[6]
Zahra El-Schich, Emmy Nilsson, Anna S Gerdtsson, Christer Wingren, and Anette Gjörloff Wingren
Future Science OA, 2015, Volume 1, Number 3
[7]
Henry J. Rozycki
Paediatric Respiratory Reviews, 2015, Volume 16, Number 4, Page 203
[8]
Gerald B. W. Wertheim
Journal of Hematopathology, 2015, Volume 8, Number 3, Page 177
[9]
Adriana Mihaela David and Romeo Zeno Cretu
Procedia - Social and Behavioral Sciences, 2014, Volume 127, Page 887
[10]
Thomas Liehr, Moneeb AK Othman, Katharina Rittscher, and Eyad Alhourani
Expert Review of Molecular Diagnostics, 2015, Volume 15, Number 4, Page 517
[11]
Gerald B. W. Wertheim, Elizabeth Hexner, and Adam Bagg
Molecular Diagnosis & Therapy, 2012, Volume 16, Number 6, Page 357
[12]
Eric J. Foss, Dragan Radulovic, Derek L. Stirewalt, Jerald Radich, Olga Sala-Torra, Era L. Pogosova-Agadjanyan, Shawna M. Hengel, Keith R. Loeb, H. Joachim Deeg, Soheil Meshinchi, David R. Goodlett, and Antonio Bedalov
Journal of Proteome Research, 2012, Volume 11, Number 10, Page 5005
[13]
Olga Blau, Rimma Berenstein, Annette Sindram, and Igor Wolfgang Blau
Leukemia & Lymphoma, 2013, Volume 54, Number 1, Page 145
[14]
Maria Braoudaki and Fotini Tzortzatou-Stathopoulou
Clinical Lymphoma Myeloma and Leukemia, 2012, Volume 12, Number 4, Page 230
[15]
S Weissmann, T Alpermann, V Grossmann, A Kowarsch, N Nadarajah, C Eder, F Dicker, A Fasan, C Haferlach, T Haferlach, W Kern, S Schnittger, and A Kohlmann
Leukemia, 2012, Volume 26, Number 5, Page 934
[16]
O. Blau, C. D. Baldus, W.-K. Hofmann, G. Thiel, F. Nolte, T. Burmeister, S. Turkmen, O. Benlasfer, E. Schumann, A. Sindram, M. Molkentin, S. Mundlos, U. Keilholz, E. Thiel, and I. W. Blau
Blood, 2011, Volume 118, Number 20, Page 5583
[17]
Bohuslav Melichar and Mario Plebani
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 10
[18]
He Zhang, Lian Liu, Cheuk-Wing Li, Huayang Fu, Yao Chen, and Mengsu Yang
Biosensors and Bioelectronics, 2011, Volume 29, Number 1, Page 89
[19]
Alexander Brobeil, Manuel Bobrich, Michaela Graf, Anke Kruchten, Wolfgang Blau, Mathias Rummel, Sabine Oeschger, Klaus Steger, and Monika Wimmer
Leukemia Research, 2011, Volume 35, Number 10, Page 1367
[20]
Christopher Moy, Catherine A Oleykowski, Ramona Plant, Joel Greshock, Junping Jing, Kurtis Bachman, Mary Hardwicke, Richard Wooster, and Yan Degenhardt
Journal of Translational Medicine, 2011, Volume 9, Number 1, Page 110
[21]
Lucy A. Godley, John Cunningham, M. Eileen Dolan, R. Stephanie Huang, Sandeep Gurbuxani, Megan E. McNerney, Richard A. Larson, Hoyee Leong, Yves Lussier, Kenan Onel, Olatoyosi Odenike, Wendy Stock, Kevin P. White, and Michelle M. Le Beau
Seminars in Oncology, 2011, Volume 38, Number 2, Page 215
[22]
Orla Maguire, Christine Collins, Kieran O'Loughlin, Jeffrey Miecznikowski, and Hans Minderman
Cytometry Part A, 2011, Volume 79A, Number 6, Page 461
[23]
V Grossmann, A Kohlmann, H-U Klein, S Schindela, S Schnittger, F Dicker, M Dugas, W Kern, T Haferlach, and C Haferlach
Leukemia, 2011, Volume 25, Number 4, Page 671
[24]
Caroline Bouakaze, Judith Eschbach, Elise Fouquerel, Isabelle Gasser, Emmanuelle Kieffer, Sophie Krieger, Sara Milosevic, Thoueiba Saandi, Catherine Florentz, Laurence Maréchal-Drouard, and Michel Labouesse
Biochemistry and Molecular Biology Education, 2010, Volume 38, Number 5, Page 296
[25]
K. Haslam, N. Chadwick, J. Kelly, P. Browne, E. Vandenberghe, C. Flynn, E. Conneally, and S. E. Langabeer
Irish Journal of Medical Science, 2010, Volume 179, Number 4, Page 507

Comments (0)

Please log in or register to comment.
Log in